Genetic Mechanisms in Interval Colon Cancers
James M. Richter(Brigham and Women's Hospital), Daniel C. Chung(Massachusetts General Hospital), Thomas R. Austin(Harvard University), A. John Iafrate(Massachusetts General Hospital), Emily J. Campbell(Harvard University), Jackie Szymonifka(Cornell University), Maria Simona Pino(Massachusetts General Hospital), Andrea Russo(Università Cattolica del Sacro Cuore), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Theodore S. Hong(Massachusetts General Hospital)
Cited by 21
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
|New England Journal of Medicine|2008|1.6k